<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03904381</url>
  </required_header>
  <id_info>
    <org_study_id>STM.C240.17.037</org_study_id>
    <nct_id>NCT03904381</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of XEN® Gel Stent and Post-operative Management in Patients With Open Angle Glaucoma</brief_title>
  <official_title>Efficacy and Safety of XEN® Gel Stent and Post-operative Management in Patients With Open Angle Glaucoma Compared to Classic Glaucoma Surgeries (Trabeculectomy and Sclerectomy) as Well as Other Minilally Invasive Glaucoma Surgery (MIGS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wroclaw Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wrocław University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wroclaw Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of postoperative management with 5-fluorouracil injections after XEN
      Gel Stent implantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unqualified success</measure>
    <time_frame>5 years</time_frame>
    <description>Unqualified success of glaucoma treatment, defined as a postoperative IOP &lt;18 mmHg and &gt;20% reduction compared with the baseline value, achieved without use of any antiglaucoma medication and with no detected glaucoma progression as assessed at the final follow-up visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Qualified success score A</measure>
    <time_frame>5 years</time_frame>
    <description>Qualified success of glaucoma treatment, defined as a postoperative IOP &lt;21 mmHg and &gt;20% reduction compared with the baseline value, achieved with or without use of antiglaucoma medication and with no detected glaucoma progression as assessed at the final follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualified success score B</measure>
    <time_frame>5 years</time_frame>
    <description>Qualified success of glaucoma treatment, defined as a postoperative IOP &lt; 18 mmHg and &gt;20% reduction compared with the baseline value, achieved with or without use of antiglaucoma medication and with no detected glaucoma progression as assessed at the final follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualified success score C</measure>
    <time_frame>5 years</time_frame>
    <description>Qualified success of glaucoma treatment, defined as a postoperative IOP ≤15 mmHg and &gt;40% reduction compared with the baseline value, achieved with or without use of antiglaucoma medication and with no detected glaucoma progression as assessed at the final follow-up visit.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Glaucoma Progression</measure>
    <time_frame>5 years</time_frame>
    <description>Glaucoma progression was evaluated with the Hodapp-Parrish-Anderson Glaucoma Grading Scale (GGS).
Staging according to the standards given in bibliography (Budenz et all in 2002)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in thickness of the retinal nerve fiber layer (RNFL)</measure>
    <time_frame>5 years</time_frame>
    <description>Difference in thickness of the retinal nerve fiber layer during the observation time frame.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in thickness of ganglion cell complex (GCC)</measure>
    <time_frame>5 years</time_frame>
    <description>Difference in thickness of ganglion cell complex during the observation time frame.</description>
  </other_outcome>
  <other_outcome>
    <measure>Short term changes in IOP after surgery</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluated with the use of water drinking test.</description>
  </other_outcome>
  <other_outcome>
    <measure>Refractive error</measure>
    <time_frame>5 years</time_frame>
    <description>Change in refractive error after glaucoma procedures</description>
  </other_outcome>
  <other_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluated on the fixed charts by trained optometrist</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual field (VF)</measure>
    <time_frame>5 years</time_frame>
    <description>Detection of the visual field abnormalities on the standard machine and during screening procedures</description>
  </other_outcome>
  <other_outcome>
    <measure>Disc damage likelihood scale (DDLS)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation disc damage likelihood scale based on the fundus photographs</description>
  </other_outcome>
  <other_outcome>
    <measure>Peripapillar and macular vessels density</measure>
    <time_frame>5 years</time_frame>
    <description>Measured on the custom-derived protocol and manufacturer software macular and peripapillar vessels density - Angio OCT (OCTA)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>stand-alone procedure of XEN implantation in phakic eyes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>stand-alone procedure of XEN implantation in pseudophakic eyes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>XEN implantation combined with cataract extraction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>5-fluorouracil subconjunctival injections were a first-choice therapy for bleb failure and were administered according to predetermined criteria.</description>
    <arm_group_label>XEN implantation combined with cataract extraction</arm_group_label>
    <arm_group_label>stand-alone procedure of XEN implantation in phakic eyes</arm_group_label>
    <arm_group_label>stand-alone procedure of XEN implantation in pseudophakic eyes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transconjunctival needling</intervention_name>
    <description>Transconjunctival needling was administered according to predetermined criteria.</description>
    <arm_group_label>XEN implantation combined with cataract extraction</arm_group_label>
    <arm_group_label>stand-alone procedure of XEN implantation in phakic eyes</arm_group_label>
    <arm_group_label>stand-alone procedure of XEN implantation in pseudophakic eyes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transconjunctival revision</intervention_name>
    <description>Transconjunctival revision was administered according to predetermined criteria.</description>
    <arm_group_label>XEN implantation combined with cataract extraction</arm_group_label>
    <arm_group_label>stand-alone procedure of XEN implantation in phakic eyes</arm_group_label>
    <arm_group_label>stand-alone procedure of XEN implantation in pseudophakic eyes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of primary open angle glaucoma

          -  trabecular meshwork visible in gonioscopy

          -  medicated IOP of ≥ 15 mmHg and ≤ 35 mmHg

          -  taking 1 to 5 IOP-lowering medications

          -  area of healthy, free and mobile conjunctiva in the target quadrant (superior-nasal)

          -  signed inform consent

        Exclusion Criteria:

          -  angle closure glaucoma

          -  secondary open angle glaucoma

          -  previous glaucoma shunt/valve in the target quadrant

          -  presence of conjunctival scarring, prior conjunctival surgery or other conjunctival
             pathologies (e.g., pterygium) in the target quadrant

          -  active inflammation (e.g., blepharitis, conjunctivitis, keratitis, uveitis)

          -  active iris neovascularization or neovascularization of the iris within 6 months of
             the surgical date

          -  anterior chamber intraocular lens

          -  presence of intraocular silicone oil

          -  vitreous present in the anterior chamber

          -  impaired episcleral venous drainage (e.g., Sturge-Weber or nanophthalmos or other
             evidence of elevated venous pressure)

          -  known or suspected allergy or sensitivity to drugs required for the surgical procedure
             or any of the device components (e.g., porcine products or glutaraldehyde)

          -  history of dermatologic keloid formation

          -  previous photorefractive keratectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Misiuk-Hojło, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of Wrocław</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ewa Wałek</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Wrocław</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joanna Przeździecka-Dołyk</last_name>
    <phone>+49605693022</phone>
    <email>joanna.przezdziecka-dolyk@umed.wroc.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Ophthalmology</name>
      <address>
        <city>Wrocław</city>
        <zip>54-622</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Przeździecka-Dołyk</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Budenz DL, Rhee P, Feuer WJ, McSoley J, Johnson CA, Anderson DR. Comparison of glaucomatous visual field defects using standard full threshold and Swedish interactive threshold algorithms. Arch Ophthalmol. 2002 Sep;120(9):1136-41.</citation>
    <PMID>12215086</PMID>
  </reference>
  <reference>
    <citation>Susanna R Jr, Vessani RM. Staging glaucoma patient: why and how? Open Ophthalmol J. 2009 Sep 17;3:59-64. doi: 10.2174/1874364100903020059.</citation>
    <PMID>19834563</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wroclaw Medical University</investigator_affiliation>
    <investigator_full_name>Joanna Przeździecka-Dołyk</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

